Check­point ends tri­al due to Russ­ian in­va­sion; Terns lines up more cash for NASH

You can count a Phase III pro­gram at Check­point Ther­a­peu­tics as the lat­est col­lat­er­al dam­age from Rus­sia’s in­va­sion of Ukraine.

The biotech $CKPT re­port­ed this morn­ing that it has had to scrap the late-stage CON­TER­NO tri­al com­bin­ing cosi­be­limab with peme­trexed and plat­inum chemother­a­py for non-squa­mous non-small cell lung can­cer af­ter the con­flict slowed en­roll­ment for the study.

Ac­cord­ing to Check­point:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER